Due to Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) has had to develop its own procedures separate from the European Medicines Agency (EMA). What new guidance has the MHRA released? Join Darshan Kulkarni as he talks with transparency expert Nirpal Virdee about the MHRA’s impact on transparency in clinical trials. We’ll also talk about how the European Medicines Agency (EMA) is dealing with the aftermath of Brexit.
Start your week off by tuning into the @Darshantalks Podcast! Host @DarshanKulkarni welcomes back guest @Emmasutcliffe to talk all things...
Be sure to tune into this episode of @Darshantalks where host @DarshanKulkarni will be discussing Patient Advocacy Leadership with guest...
Join host @DarshanKulkarni on this episode of @Darshantalks as he welcomes guest, @RachelKane, to talk about Customer Centric Engagement.
